DYDROGESTERONE AS AN ALTERNATIVE TO SUPPRESS LH SURGE IN ART CYCLES

The aim of this study is to evaluate the effectiveness Dydrogesterone in PPOS protocols for IVF/ICSI cycles or Oocyte cryopreservation both blocking LH surge as well number metaphase II oocytes. 550 plus 186 oocyte from January 2018 December 2020, no age restriction. All patients were given Follitropin delta (Rekovelle®, Ferring Pharmaceuticals) Menotropin (Menopur®, a fixed daily SC dose. Clinical decision led GnRH antagonist (CTA-Cetrorelix acetate, Cetrotide®, Merck) 0,25 mg/d initiated flexible shedule presence one follicle ≥ 14 mm and continued throughout stimulation period (326 cycles) dydrogesterone (DYG), 10 mg 8/8 hs (Duphaston®, Abbott) combined gonadotrophin beginning until day after trigger (410 cycles). final follicular maturation was performed when there three more follicles 17 diameter either with 250 recombinant hCG (Choriogonadotropin alfa, Ovidrel®, agonist, 2 ampules (triptorelin acetate Gonapeptyl Daily®, Pharmaceuticals). Cancelling criteria: by 15. retrieval took place 36 hours trigging. Primary outcome incidence premature surge. Secondary outcomes included 15 < 18 on day, oocytes, cancelled OHSS symptoms. Statistics Mann-Whitney test. DYG group had mean significantly higher (37.13 x 37.81-p 0.02) but differences parameters BMI (25.25 24.37), days (10.03 10.15), AMH values (1.95 1.90), AFC (12.47 12.29). Differently, observed between (3.04 2.65-p (3.72 4.67), tendency greater larger group. Metaphase oocytes (6.57 6.86) similar groups. No patient experienced (3.08 3.64) case single 20 aspirated follicle. There happened cancelling. moderate severe ovarian hyperestimulation syndrome, even > 3 ng/mL. an eligible tool intended freeze-all / PGT-A preservation. It can also be considered embryo banking preventing